9 Morabito F, Stelitano C, Callea I, Dattola A, Console G, Puci G et al. Acute myeloid leukemia (AML) is the most common acute leukemia in adults, whereas it constitutes only B15-20% of childhood leukemias. AML is a biologically and clinically heterogeneous disease, for which cytogenetic findings have proved essential for stratifying patients into prognostic subgroups. Although a large proportion of AML display normal karyotype (adults 35-50%, children 25%), 1 recent developments have revealed molecular markers, such as the mutational status of the FMS-related tyrosine kinase 3 (FLT3), Nucleophosmin (NPM1) and CEBPA genes, to aid further subdivision of AML patients with normal karyotype. To date, these molecular prognosticators are well established in adult AML, 2 whereas they have been less studied in pediatric AML. In a recent study, we performed an extensive analysis of DNA-based markers (for example, FLT3, NPM1, CEBPA and WT1 genes) and RNA-based markers in a large cohort of uniformly treated patients from the Nordic countries, further supporting FLT3 and NPM1 as key prognostic markers also in pediatric AML. 3 One of the major obstacles when working with DNA samples with great clinical/scientific value, such as tumor samples from leukemia patients, is the limited amounts of DNA for genetic analysis. Wholegenome amplification (WGA) has therefore emerged as an important method for reproducing abundant quantities of DNA as an alternative source of DNA for genetic analysis. In recent years, implementation of WGA DNA has increased drastically for different type of applications, such as genome-wide analysis of singlenucleotide polymorphisms (SNP) and copy number variations (CNV). 4, 5 However, the usefulness of WGA method is mainly based on the presumption that the entire genome is amplified with minimal amplification bias. One of the most commonly used WGA methods is the multiple displacement amplification (MDA), which replicates the genome isothermally using random hexamer primers and DNA polymerase, such as Phi29, followed by strand displacement. Even though several studies on Phi29 have demonstrated that it has high genome coverage, little amplification bias and high accuracy compared with genomic DNA controls, 6, 7 controversial results have also been reported. 8, 9 In our aforementioned study on pediatric AML, we initially planned only to perform the DNA mutational analysis using WGA DNA, and later confirm the identified mutations using original DNA samples in order to save original DNA, as this sample cohort is one of the rare and larger population-based collections in the world. However, to study the impact of WGA DNA as a source of DNA, we instead decided to perform WGA for all 216 AML samples using the GenomiPhi V2 DNA Amplification Kit (Amersham Biosciences, Uppsala, Sweden), and in parallel carried out DNA mutational analysis for the FLT3 and NPM1 genes using original and WGA DNA. 3 To rule out the possibility of any sample misplacement or the WGA process itself, all samples underwent WGA two times (set I and set II) using the same kit. FLT3-ITD and NPM1 mutations were analyzed by PCR amplification, followed by subsequent fragment analysis as described previously. 3, 10 To
Accepted article preview online 31 August 2012; advance online publication, 21 September 2012 screen for FLT3-TKD mutations (D835 or I836), DNA was PCRamplified and followed by restriction enzyme digestion as described previously.
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As can be seen in Table 1 , the original DNA and WGA DNA from set I and II rendered apparent differences in the results from the DNA mutational analysis, in particular for FLT3-ITD and NPM1. For example, in cases with FLT3-ITD mutations in original DNA, the mutant peaks could not be observed in seven WGA DNA samples, despite clear peaks in the original DNA samples (Figure 1a) . Furthermore, even the peak areas for the mutant FLT3-ITD peaks could vary between WGA set samples and original DNA samples. In the case of NPM1 mutations, the discrepancies in the results occurred not only because of lack of the mutant peaks after fragment analysis in WGA samples (six cases), but also because of lack of PCR products even after several attempts of PCR amplification (three cases). In contrast, FLT3-TKD mutations showed very minor differences between the three sets compared with the other mutations. In fact, WGA set II showed the same results compared with the original DNA. That notwithstanding, when all the samples with FLT3-TKD mutations for both WGA and original DNA were run on gels, there was a clear difference between intensities of the uncut (mutant) and cut (wild-type) DNA bands (Figure 1b) . This indicates that even though the mutations are present in WGA DNA, the percentage of the mutant copies of DNA may vary between WGA and original DNA of the same sample.
In summary, using WGA DNA for mutational detection may give unsolicited discrepant results compared with original DNA, in particular when applying fragment analysis for detection of mutation peaks. Until now the assessment of WGA DNA-induced bias has been analyzed for genome-wide studies such as SNP, CNV and CGH array profiles. 4, 5, 9 Also, studies comparing different methods of WGA, such as degenerate oligonucleotide primed PCR, primer extension preamplification and MDA, were mainly focused to find the most optimal method. 12 In our study, we applied the MDA method, which is considered reliable with less extent of bias during amplification because of a higher proof-reading capacity compared with other methods. Despite this, our data indeed shows that WGA DNA as a source for mutational analysis can significantly underestimate the frequency of mutations. As a consequence of amplification bias, regions of the genome could be completely lost or altered, resulting in a lack of amplification of the desired product, as observed in the case of NPM1 mutations. Also, WGA samples did not always show the mutant FLT3-ITD peaks after fragment analysis, and such samples would incorrectly be considered normal. We conclude that researchers should be very cautious while using WGA samples, at least for purposes including fragment analysis, whereas analysis of certain mutations using restriction enzyme digestion appears to be less vulnerable. During recent years, a variety of novel molecular markers have been proposed as prognostic factors in chronic lymphocytic leukemia (CLL), which has significantly improved the subdivision of the disease. One of the strongest markers is fluorescence in situ hybridization detection of certain genomic aberrations, that is, del(11q), trisomy 12, del(13q) and del(17p), which is now included in routine diagnostics to guide decisions about therapy. 1 More specifically, CLL patients with the 13q deletion (as a single aberration) have a more indolent disease course, whereas patients with 11q or, in particular, 17p deletions experience a more rapid disease progression with need of early treatment, and a generally poor overall survival.
1,2 Notably, CLL patients with 17p deletions and/or TP53 mutations belong to the category of patients with the worst outcome in CLL, as they generally do not respond to the current state-ofthe-art treatment with fludarabine, cyclophosphamide and rituximab. 1, 3 More recently, the advent of next-generation sequencing has revealed a number of novel genes to be frequently mutated in CLL, such as NOTCH1, SF3B1, BIRC3 and MYD88. [4] [5] [6] [7] [8] [9] [10] In the pivotal studies, NOTCH1 mutations were identified in up to 12% of patients, and the mutations were strongly associated with progressive disease, treatment resistance, increased risk Abbreviations: CLL, chronic lymphocytic leukemia; SF3B1, splicing factor 3B subunit 1; N.R., not reached. *P-value represents a combined P-value for the analysis and indicates that at least one group differs significantly from the rest. Median value is given in months.
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